ISSN: 2353-8201
Prenatal Cardiology
Current issue Archive About the journal Editorial board Abstracting and indexing Contact Instructions for authors Ethical standards and procedures
1/2020
 
Share:
Share:
more
 
 
abstract:
Review paper

Cardiac birth defects induced by maternal medications

Gideon Koren
1, 2

1.
Adelson Faculty of Medicine, Ariel University, Ariel, Israel
2.
Motherisk Israel Program, Shamir Medical Center, Zerifin, Israel
Prenat Cardio 2020
Online publish date: 2020/04/27
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Cardiovascular malformations form the largest group of congenital anomalies, typically quoted at 0.8% of all live births. Several medicinal drugs have been proven to cause cardiovascular malformations. We discuss here the risks of the major known medications, including lithium, valproic acid, ondansetron, methylphenidate, topiramate, and the newly recognised dydrogesterone. In contrast, we discuss the controversial and debated effects of selective serotonin reuptake inhibitors (SSR) and selective serotonin norepinephrine reuptake inhibitors (SNRI). Subsequently we describe the principles of counselling pregnant women and those planning pregnancy, who are exposed to these drugs.
keywords:

lithium, ondansetron, cardiac malformations, maternal medications, dydrogesterone

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe